Business Wire·Jul 7, 2026, 8:00 AM ET

Organon to Present New Analysis on VTAMA® (tapinarof) cream, 1%, at the 2026 Society for Pediatric Dermatology Annual Meeting

Organon will present a pooled post hoc analysis of Phase 3 data on VTAMA cream efficacy & safety across pediatric & adult age groups at the 2026 Society for Pediatric Dermatology Annual Meeting in Minneapolis from July 22–25, 2026.
The presentation titled "Tapinarof 1% Cream in Atopic Dermatitis: Consistent Efficacy Across Age Groups From Pooled ADORING Trials" is scheduled for Thursday, July 23, 2026, from 9:50–10:20 AM Central Time.
The analysis combines data from the pivotal ADORING 1 & ADORING 2 trials plus the 48-week open-label extension trial ADORING 3 for moderate to severe atopic dermatitis.
VTAMA cream is the only aryl hydrocarbon receptor agonist indicated for plaque psoriasis in adults & atopic dermatitis in adults & pediatric patients aged 2 years & older.
The American Academy of Dermatology provides strong recommendations for VTAMA use in atopic dermatitis for adults & pediatric patients aged 2 years & older.
Common adverse reactions for atopic dermatitis include upper respiratory tract infection, folliculitis, lower respiratory tract infection, headache, asthma, vomiting, ear infection, pain in extremity, & abdominal pain.